Special Issue

Gynecologic Cancer: Risk Factors, Interception and Prevention

Message from the Guest Editors

Gynecologic cancers, including ovarian, endometrial and cervical cancers, account for approximately 100,000 new cases and over 30,000 deaths per year in the US. The prevention and interception of these cancers would greatly impact outcomes and significantly reduce mortality rates. For ovarian cancer, screening in the general population is not considered effective, and therefore most cases of this cancer are diagnosed at a late stage with a poor survival rate. Endometrial cancer incidence and mortality is markedly increasing in recent years, due in large part to increasing obesity rates. Cervical cancer has had the benefit of the availability of both screening and prevention. Equity in the dissemination and implementation of these prevention and screening methods is essential for early diagnosis and treatment. These opportunities and challenges related to the diagnosis and high mortality of these gynecologic cancers emphasize the importance of identifying women at higher risk for these cancer types, and providing prevention/interception interventions to decrease the incidence and improve outcomes.

Guest Editors

Dr. Brandy Heckman-Stoddard

Division of Cancer Prevention, National Cancer Institute, Rockville, MD 20850, USA

Dr. Goli Samimi

Division of Cancer Prevention, National Cancer Institute, Rockville, MD 20850, USA $\,$

Deadline for manuscript submissions

closed (30 September 2025)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/179138

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

